In NSCLC naive to PD-(L)1 inhibitors, ORR: 26% with sequentially administered vibostolimab plus pembrolizumab.In patients with anti-PD-1/PD-L1-refractory NSCLCORR 3%vs singleVibostolimab (anti-TIGIT) ORR 3%(NCT02964013) (271). This evidence concerns the gene CD274 and non-small cell lung carcinoma.